WebJul 13, 2024 · Why Cyteir Technology Is Impressive: Cyteir focuses on addressing the synthetic lethality of cells to treat a range of cancers, Ahmad noted. The company's lead asset CYT0851 is in a Phase 1/2... WebJul 7, 2024 · Cyteir recently appointed Paul Secrist, Ph.D., to the position of chief scientific officer. Dr. Secrist began his pharmaceutical and biotechnology career in 1996 and has since served in scientific leadership roles at companies including OSI Pharmaceuticals, Aton Pharma, Merck & Company and AstraZeneca Pharmaceuticals.
Quoin Pharmaceuticals Completes Merger and Will Commence
WebCyteir is a clinical-stage oncology company that is focused on the development of CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters. Cyteir’s … 99 Hayden Ave., Building B, Suite 450, Lexington, MA 02421. 857.285.4140. … Joseph S. Zakrzewski Independent Investor & Chairman, Cyteir Therapeutics. … Cyteir is a clinical-stage oncology company that is focused on the development of … For Patients Clinical trials underway CYT-0851 CYT-0851 is a novel, potent, small … Publications RECENT PUBLICATIONS First-in-Human Phase I/II Study of CYT … Contact Cyteir Fill out the form below and we will respond shortly. Contact … Cyteir Therapeutics Secures $80 Million in Series C Financing to Advance Clinical … WebJun 21, 2024 · Cyteir is the eighth Massachusetts-based biotech to hit public markets this year. Its IPO came exactly one day after Verve Therapeutics' public debut; that company … tnf x tw men\u0027s flight vectiv
Cyteir Therapeutics - Crunchbase Company Profile
WebIdentification of the Mechanism of Action of CYT-0851, An Inhibitor of Monocarboxylate Transporter (MCT) Mediated Lactate Transport. Bradley, W.D., et.al., 34th EORTC-NCI-AACR Symposium 2024. VIEW PUBLICATION →. 128 Spring St, Building A Suite 510, Lexington, MA 02421. 857.285.4140. WebMar 2, 2024 · The biotech had originally laid out plans to get the monocarboxylate transporter inhibitor into the clinic by the end of 2024, but the candidate was sacrificed to save cash. After raising $29 million in early 2024, Cyteir joined the public biotech boom just as it was beginning to slide, closing a $133.2 million IPO in June 2024. WebFeb 22, 2024 · Her firm is impenetrably named Aperiomics. Aperio is Latin for “reveal.” (“Branding is not my forte,” she said.) “It’s really frustrating,” the 45-year-old medical … tnf-α rabbit pab